tetano
Editor, Senior Moderator
Clin Immunol
. 2025 Mar 3:274:110471.
doi: 10.1016/j.clim.2025.110471. Online ahead of print. Autoantibody development is associated with clinical severity of COVID-19: A cohort study
Marie Brinkmann[SUP] 1 [/SUP], Ludwig Traby[SUP] 2 [/SUP], Manuel Kussmann[SUP] 2 [/SUP], Matthias Weiss-Tessbach[SUP] 3 [/SUP], Nina Buchtele[SUP] 4 [/SUP], Thomas Staudinger[SUP] 4 [/SUP], Elias Gaidoschik[SUP] 1 [/SUP], Thomas Perkmann[SUP] 5 [/SUP], Helmuth Haslacher[SUP] 5 [/SUP], Franz Ratzinger[SUP] 5 [/SUP], Winfried F Pickl[SUP] 6 [/SUP], Karim El-Gedawi[SUP] 7 [/SUP], Melanie Feichter[SUP] 7 [/SUP], Ellen Gelpi[SUP] 8 [/SUP], Romana Höftberger[SUP] 8 [/SUP], Peter Quehenberger[SUP] 5 [/SUP], Rodrig Marculescu[SUP] 5 [/SUP], Daniel Mrak[SUP] 9 [/SUP], Kastriot Kastrati[SUP] 9 [/SUP], Helga Lechner-Radner[SUP] 9 [/SUP], Daniela Sieghart[SUP] 9 [/SUP], Daniel Aletaha[SUP] 1 [/SUP], Stefan Winkler[SUP] 2 [/SUP], Michael Bonelli[SUP] 10 [/SUP], Lisa Göschl[SUP] 1 [/SUP]
Affiliations
Viral infections, including respiratory diseases such as Coronavirus disease 2019 (COVID-19), are hypothesized to contribute to the onset of autoimmune disorders. Although elevated levels of autoantibodies have been observed following COVID-19, the role of specific autoantibodies linked to autoimmune diseases and their correlation with disease severity remains poorly defined. In this study, we used a comprehensive autoantibody panel to assess the autoantibody production across different cohorts of COVID-19 patients, categorized by disease severity. We also compared patients with severe COVID-19 to a control group with other severe, non-COVID-related diseases. Our findings indicate that the severity of COVID-19 corresponds to the overall production of specific autoantibodies, which are particularly associated with COVID-19. This association might predispose to an increased risk for the development of autoimmune conditions after a severe course of COVID-19.
Keywords: Autoantibodies; Autoimmune triggers; COVID-19; Extracorporeal membrane oxygenation; Intensive care unit.
. 2025 Mar 3:274:110471.
doi: 10.1016/j.clim.2025.110471. Online ahead of print. Autoantibody development is associated with clinical severity of COVID-19: A cohort study
Marie Brinkmann[SUP] 1 [/SUP], Ludwig Traby[SUP] 2 [/SUP], Manuel Kussmann[SUP] 2 [/SUP], Matthias Weiss-Tessbach[SUP] 3 [/SUP], Nina Buchtele[SUP] 4 [/SUP], Thomas Staudinger[SUP] 4 [/SUP], Elias Gaidoschik[SUP] 1 [/SUP], Thomas Perkmann[SUP] 5 [/SUP], Helmuth Haslacher[SUP] 5 [/SUP], Franz Ratzinger[SUP] 5 [/SUP], Winfried F Pickl[SUP] 6 [/SUP], Karim El-Gedawi[SUP] 7 [/SUP], Melanie Feichter[SUP] 7 [/SUP], Ellen Gelpi[SUP] 8 [/SUP], Romana Höftberger[SUP] 8 [/SUP], Peter Quehenberger[SUP] 5 [/SUP], Rodrig Marculescu[SUP] 5 [/SUP], Daniel Mrak[SUP] 9 [/SUP], Kastriot Kastrati[SUP] 9 [/SUP], Helga Lechner-Radner[SUP] 9 [/SUP], Daniela Sieghart[SUP] 9 [/SUP], Daniel Aletaha[SUP] 1 [/SUP], Stefan Winkler[SUP] 2 [/SUP], Michael Bonelli[SUP] 10 [/SUP], Lisa Göschl[SUP] 1 [/SUP]
Affiliations
- PMID: 40044018
- DOI: 10.1016/j.clim.2025.110471
Viral infections, including respiratory diseases such as Coronavirus disease 2019 (COVID-19), are hypothesized to contribute to the onset of autoimmune disorders. Although elevated levels of autoantibodies have been observed following COVID-19, the role of specific autoantibodies linked to autoimmune diseases and their correlation with disease severity remains poorly defined. In this study, we used a comprehensive autoantibody panel to assess the autoantibody production across different cohorts of COVID-19 patients, categorized by disease severity. We also compared patients with severe COVID-19 to a control group with other severe, non-COVID-related diseases. Our findings indicate that the severity of COVID-19 corresponds to the overall production of specific autoantibodies, which are particularly associated with COVID-19. This association might predispose to an increased risk for the development of autoimmune conditions after a severe course of COVID-19.
Keywords: Autoantibodies; Autoimmune triggers; COVID-19; Extracorporeal membrane oxygenation; Intensive care unit.